“To build a new development pattern, we should revitalize China’s international markets, unblock China’s big cycle, and build an open China International ‘double cycle’ pattern.” Deng Xiafei, member of the Standing Committee of the provincial people’s Political Consultative Conference and President of Humanwell Healthcare (Group) Co.Ltd(600079) was pleased to see that the business environment in Hubei has been continuously optimized and the biomedical industry has a strong development momentum, showing a good trend of vigorous development——
In 2021, 17 pharmaceutical enterprises in the province entered the top 500 of the national pharmaceutical industry, of which Humanwell Healthcare (Group) Co.Ltd(600079) group maintained the position within the top 30 of the national pharmaceutical industry;
It has successively introduced world-class Chinese enterprises in the biomedical field such as Pfizer, Lianying and Mindray, and cultivated a number of industry leaders and high growth enterprises such as Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) and Anhan technology.
Deng Xiafei introduced that as a leading enterprise in the internationalization of China Meheco Group Co.Ltd(600056) preparations, Humanwell Healthcare (Group) Co.Ltd(600079) is actively layout the internal and external “double circulation” relying on China’s large circulation.
Based on the Chinese market, Humanwell Healthcare (Group) Co.Ltd(600079) occupies a leading position in the market segments of narcotic drugs, fertility regulating drugs and ethnic drugs.
At the same time, Humanwell Healthcare (Group) Co.Ltd(600079) firmly take the road of international development and carry out industrial layout for the global pharmaceutical market. At present, more than 80 products have been exported to more than 70 countries and regions around the world. Overseas business covers mature markets in Europe and America and emerging markets such as South America, Southeast Asia, Central Asia, East Africa and West Africa.
At the two sessions, focusing on the theme of continuously promoting the agglomeration and development of biomedical industry and helping the construction of “51020” modern industrial clusters, Deng Xiafei suggested that more attention should be paid to innovation, the development of the whole industrial chain and the construction of basic platforms, and identify the growth points of development, especially in medical devices, medical emergency products, health intelligent devices, cell therapy, etc Potential areas should focus on efforts to accelerate the cultivation of new development advantages.
